secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123273
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q3 total revenue $70M (+37% YoY); YTD net income $20M, non-GAAP $45M
-----------------------------------------------------------------------------

- Q3 total revenue $70.1M (+37% YoY); YTD revenue $208.7M (+49% YoY); YTD net income $20M.
- Tyvaso DPI royalties up 34% to $27.1M (Q3) and 48% YTD to $75.3M; collaboration revenue +78% on manufacturing.
- Afrezza net revenue up 12% to $15.0M (Q3); V-Go net revenue up 5% to $4.7M.
- Pipeline: MNKD-101 Phase 3 global expansion; MNKD-201 Phase 1 complete, FDA meeting 1H 2025; INHALE-3 positive; pediatric data due Q4.
- Cash and investments $268.4M; $5.3M bargain purchase gain from Pulmatrix deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000095017024123273/0000950170-24-123273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000095017024123273/mnkd-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer